Crossmark

Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both

Crossref DOI link: https://doi.org/10.1038/s41388-022-02200-5

Published Online: 2022-01-31

Published Print: 2022-03-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ma, Guangzhi

Deng, Yunfu

Qian, Luxi

Vallega, Karin A.

Zhang, Guojing

Deng, Xingming

Owonikoko, Taofeek K. https://orcid.org/0000-0002-7724-7728
Ramalingam, Suresh S.

Fang, Douglas D.

Zhai, Yifan

Sun, Shi-Yong https://orcid.org/0000-0002-0117-8826
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA217691)
License Information

Text and Data Mining valid from 2022-01-31

Version of Record valid from 2022-01-31
More Information

Article History

Received: 16 August 2021

Revised: 4 January 2022

Accepted: 18 January 2022

First Online: 31 January 2022

Competing interests

: TKO is on consulting/advisory board for Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, Takeda, Bristol-Myers Squibb, MedImmune, Amgen, AstraZeneca and Boehringer Ingelheim. SSR is on consulting/advisory board for AstraZeneca, BMS, Merck, Roche, Tesaro and Amgen. YZ and DDF are full-time employees and equity shareholders of Ascentage Pharma. SYS received a research fund from Ascentage Pharma. Other authors disclose that they have no potential conflicts of interest.

Document is current

Any future updates will be listed below